• The number of people requiring interventions against NTDs fell to 1.41 billion in 2024: a 36% reduction since 2010 and 19% since 2020.
• By June 2026, 63 countries had eliminated at least one NTD, up from 42 at the end of 2020, and 90 acknowledgement processes had been completed. Togo became the first country to eliminate four NTDs.
• The integrated treatment coverage index for preventive chemotherapy reached its highest value since 2020, and 43 countries have adopted integrated strategies for skin NTDs, exceeding the 2030 target of 40 six years ahead of schedule.
• More countries have integrated NTDs into national health strategies, essential service packages and disability management guidelines.

• Nevertheless, most indicators remain below the 2030 targets. Disability-adjusted life years fell by 18% between 2015 and 2021 but have since stagnated. Neither eradication programme (dracunculiasis and yaws) is on track. Deaths from vector-borne NTDs have increased, although the case fatality rate for dengue has decreased. Only a minority of endemic countries report on all their relevant NTDs or report gender-disaggregated data, access to WASH in endemic areas remains below universal coverage, and adoption of guidelines has generally outpaced implementation.

• Programmatic action: WHO has released about 260 NTD publications since 2021. New tools have begun to reach programmes, including the paediatric praziquantel formulation arpraziquantel, prequalified dengue vaccines, approved chikungunya vaccines and simplified oral treatments for human African trypanosomiasis. The diagnostics pipeline has grown to 29 target product profiles across 15 diseases.
• Integration and cross-cutting approaches: NTD interventions are increasingly co-delivered with immunization, antenatal care, school health and noncommunicable disease services. However, most endemic countries do not yet include them in universal health coverage packages, and collaboration with the WASH sector remains limited.

• Country ownership and sustainability: more countries are integrating NTDs into national health plans, and some have made initial domestic budget commitments. However, most programmes remain dependent on external financing, which has contracted sharply and is concentrated among a small number of donors.
• Disease-specific progress: progress is uneven. Only three disease-specific indicators met their 2025 milestone: vaccine development for chikungunya, the case fatality rate for dengue, and the availability of WHO-recommended polyspecific antivenoms for snakebite envenoming. Across the portfolio, the gap assessments point to shared priorities: affordable point-of-care diagnostics, stronger surveillance (including post-elimination and One Health surveillance), sustained access to medicines, and wider use of WASH and vector control.

Five interdependent risks threaten the 2030 targets, all amplified by the financing contraction of 2025: concentrated and declining financing; conflict, displacement and climate change; incomplete integration into national health systems; gaps in diagnostics and medicines; and unmet need concentrated among the populations least served.

The evaluation calls for increasing and institutionalizing domestic financing while sustaining external support, treating conflict and environmental change as structural realities, making integration the default delivery model, embedding specialist capacity in national institutions, funding research through to prequalified products, and treating equity as a design requirement.